Literature DB >> 28457404

Lung Ultrasound and Pulmonary Function Test in Cirrhotic Patients.

P Osni Leão Perin1, I de Fátma Ferreira Santana Boin2, A M Oliveira da Silva3, F Chueiri Neto4, L C Martins5.   

Abstract

Lung ultrasound (LU) is useful in the diagnosis of pulmonary interstitial-alveolar syndrome (IAS) when B-lines are detected. Its prevalence and effect in lung function is not well studied in cirrhotic patients. The objective of this study was to detect the prevalence of interstitial-alveolar involvement with LU and correlate with pulmonary function test to distinguish the effect of ascites and B-lines in pulmonary function. This was an observational single-center study with 49 patients listed for liver transplantation submitted for LU and pulmonary function tests. Patients were divided into 4 groups: no ascites and no B-lines (n = 19), B-lines only (n = 19), ascites only (n = 6), and ascites and B-lines (n = 5). There was a worse forced vital capacity (FVC) in patients with B-lines only (76.1% ± 9.2; P = .0058) and ascites only (66.8% ± 10.2; P = .0010). 1-second forced expiratory volume (FEV1) also was lower in patients with B-lines only (78.5% ± 10.3; P = .0001), ascites only (71.3% ± 13.2; P = .0004), and B-lines and ascites (74.2% ± 7.6; P = .0035). Model for End-Stage Liver Disease score was worse in the group with ascites and B-lines (22.4 ± 10.1; P = .0229). B-Lines reduced FVC and FEV1 in our study and may be an independent factor in worsening pulmonary function in these patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28457404     DOI: 10.1016/j.transproceed.2017.01.046

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

Review 1.  Point-of-Care Thoracic Ultrasonography in Patients With Cirrhosis and Liver Failure.

Authors:  Kamal Kajal; Madhumita Premkumar; Sreedhara B Chaluvashetty; Harish Bhujade; Anand V Kulkarni
Journal:  Cureus       Date:  2021-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.